Brokerages expect Repligen Co. (NASDAQ:RGEN) to report sales of $50.33 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Repligen’s earnings, with estimates ranging from $49.93 million to $50.62 million. Repligen posted sales of $41.61 million in the same quarter last year, which suggests a positive year-over-year growth rate of 21%. The firm is scheduled to issue its next quarterly earnings report on Thursday, February 28th.
On average, analysts expect that Repligen will report full-year sales of $192.43 million for the current year, with estimates ranging from $192.02 million to $192.71 million. For the next financial year, analysts forecast that the company will report sales of $219.06 million, with estimates ranging from $215.00 million to $223.30 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Repligen.
Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.02. The company had revenue of $49.53 million during the quarter, compared to analyst estimates of $46.69 million. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The firm’s quarterly revenue was up 35.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.15 earnings per share.
NASDAQ RGEN traded up $0.11 during trading hours on Friday, hitting $55.35. 2,062 shares of the company’s stock traded hands, compared to its average volume of 425,146. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of 80.20, a price-to-earnings-growth ratio of 3.62 and a beta of 0.96. Repligen has a 52 week low of $29.56 and a 52 week high of $70.50.
In other news, Director Thomas F. Ryan, Jr. sold 1,763 shares of the business’s stock in a transaction on Monday, November 5th. The shares were sold at an average price of $65.75, for a total value of $115,917.25. Following the transaction, the director now owns 3,225 shares of the company’s stock, valued at $212,043.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jon Snodgres sold 31,753 shares of the business’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $63.49, for a total transaction of $2,015,997.97. Following the completion of the transaction, the chief financial officer now directly owns 32,344 shares in the company, valued at approximately $2,053,520.56. The disclosure for this sale can be found here. Insiders sold 33,827 shares of company stock worth $2,148,846 in the last three months. Insiders own 1.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in RGEN. Bank of New York Mellon Corp lifted its holdings in shares of Repligen by 2.9% in the second quarter. Bank of New York Mellon Corp now owns 498,849 shares of the biotechnology company’s stock worth $23,466,000 after buying an additional 14,041 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Repligen in the second quarter worth $135,000. Schwab Charles Investment Management Inc. raised its stake in Repligen by 6.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 202,201 shares of the biotechnology company’s stock valued at $9,512,000 after purchasing an additional 11,784 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Repligen during the second quarter valued at $250,000. Finally, BlackRock Inc. raised its stake in Repligen by 9.1% during the second quarter. BlackRock Inc. now owns 5,851,161 shares of the biotechnology company’s stock valued at $275,239,000 after purchasing an additional 485,777 shares in the last quarter. 94.35% of the stock is currently owned by hedge funds and other institutional investors.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.